Ionis Pharmaceuticals (NASDAQ:IONS) saw its market capitalization shrink by roughly $877 million in after-hours trading on Friday, September 4, 2026, after a pivotal Phase 3 trial for its cardiovascular drug pelacarsen failed to meet its primary endpoint. The stock dropped 9.1% to $52.81, briefly touching a low of $50.78 before recovering slightly.
The selloff was steep, exceeding the maximum $625 million in contingent payments that Ionis had disclosed it could receive from Royalty Pharma under a 2023 transaction. Investors were not only repricing those potential payments but also the value of retained royalties on pelacarsen and the broader prospects of the company's cardiovascular program.
Pelacarsen: Biology Worked, But Clinical Benefit Didn't Follow
The Lp(a)HORIZON trial enrolled 8,323 patients with established cardiovascular disease and elevated levels of lipoprotein(a), a genetically inherited risk factor. While pelacarsen substantially reduced Lp(a) levels, the reduction did not translate into a statistically significant decrease in major adverse cardiovascular events compared to placebo. The primary composite endpoint included cardiovascular death, nonfatal heart attack, nonfatal stroke, and urgent coronary revascularization requiring hospitalization.
“These are not the results we hoped for,” said Shreeram Aradhye, Novartis's development chief, in a statement. Full data will be presented at an upcoming medical congress, and neither company has indicated any plans for regulatory submission at this time.
Market Impact and Investor Reaction
Novartis (NYSE:NVS), which developed and funded the trial, also saw its U.S. shares decline another 5.0% in after-hours trading, following a 1.9% drop during the regular session. The market's reaction underscores the high stakes of the program, which was seen as a potential blockbuster for both companies.
Ionis's after-hours decline was particularly sharp, given that the company had already factored in the possibility of milestone payments from Royalty Pharma. The $877 million loss in market value is significantly larger than those potential payments, suggesting investors are also reassessing Ionis's retained 75% royalty interest in pelacarsen and the company's overall cardiovascular pipeline.
Royalty Structure and Financial Implications
Under a 2023 deal, Royalty Pharma paid Ionis $500 million for a 25% stake in future pelacarsen royalties, as well as a portion of SPINRAZA royalties. Ionis retained the remaining 75% of pelacarsen royalties. The deal also included provisions for up to $625 million in additional payments, contingent on regulatory approval and sales milestones. With the trial's failure, those payments are now unlikely to materialize, and the value of Ionis's retained royalty stream has been severely diminished.
Ionis has not yet quantified the impact of the trial failure on its financial outlook. The company is expected to provide more clarity in its next quarterly report.
Ionis's Commercial Base and Pipeline
Despite the setback, Ionis still has a commercial foundation. The company ended June with $2.1 billion in cash and short-term investments. Its two wholly owned products, TRYNGOLZA and DAWNZERA, generated combined U.S. sales of $31 million in the second quarter, with full-year 2026 guidance of $210 million to $230 million.
Analysts had an average price target of $88.00 before the trial result, implying significant upside from Friday's close. However, those targets are likely to be revised downward in the coming days. The company still aims to achieve cash-flow breakeven by 2028, but the loss of pelacarsen revenue expectations adds pressure to its other pipeline programs.
What's Next for Ionis and the Field
The failure of pelacarsen is a major blow to the field of Lp(a) lowering therapies, which had been seen as a promising new frontier in cardiovascular risk reduction. While the biology was confirmed, the lack of clinical benefit in the overall population raises questions about the approach. Subgroup analyses may reveal whether certain patient populations could still benefit, but those data were not released on Friday.
For Ionis, the focus now shifts to its other pipeline assets and the successful launch of its commercial products. The company's ability to generate revenue from TRYNGOLZA and DAWNZERA will be critical to offsetting the loss of pelacarsen's potential. Investors will also be watching for any updates on the company's broader cardiovascular antisense programs, which may now face increased scrutiny.
Friday's results have settled one question: lowering Lp(a) did not reduce cardiovascular events in the overall trial. The next debate will center on what Ionis can achieve without pelacarsen, and whether its other programs can fill the void.
